期刊
JOURNAL OF PAIN
卷 10, 期 11, 页码 1146-1150出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.jpain.2009.04.006
关键词
Neuropathic pain; chemotherapy induced peripheral neuropathy; breast cancer; survivors; epidemiology
资金
- NATIONAL CANCER INSTITUTE [CA109043]
- Pfizer, Inc.
Neuropathic pain (NP) remains difficult to control for a significant number of patients with cancer. Chemotherapy-induced peripheral neuropathy (CIPN) has been postulated as an initial stage in the development of NP. To assess whether CIPN (defined as National Cancer Institute Common Toxicity Criteria grade 2 or higher) was associated with NP we conducted a survey of breast cancer patients who had participated in clinical trials of paclitaxel. Of the 430 potential respondents, 240 responded to the survey. Results showed that 64% experienced CIPN during paclitaxel treatment. Follow-up survey data revealed that 27% of those with CIPN were subsequently diagnosed with NP. Logistic regression analyses showed that those who had experienced CIPN were 3 times more likely to develop NP (95% confidence interval = 1.2-7.2; P<.001), which persisted in the multivariate logistic model. In addition, NP patients reported twice as many visits to their health care provider (P=.02) and had taken more prescription (50% vs 19%; P=.001) and over-the-counter medications (62.5% versus 45%; P=.08) for pain than those without NP. The results of this study confirm that CIPN is a predictor of NP suggesting that survivors treated with paclitaxel should be regularly monitored for NP beyond treatment. Perspective: The survival rates of breast cancer patients have steadily improved over recent years, thus, research into symptoms that persist after treatment is important. We found CIPN as a predictor of NP Understanding the epidemiology of NP in breast cancer patients has high clinical and public health significance. (C) 2009 by the American Pain Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据